289 related articles for article (PubMed ID: 31564917)
1. OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer.
Deng J; Zhao S; Zhang X; Jia K; Wang H; Zhou C; He Y
Onco Targets Ther; 2019; 12():7347-7353. PubMed ID: 31564917
[TBL] [Abstract][Full Text] [Related]
2. In Situ Reprogramming of Tumors for Activating the OX40/OX40 Ligand Checkpoint Pathway and Boosting Antitumor Immunity.
Gao Y; Zhao J; Huang Z; Zhao H; Guo Z; Ma S; Tang X; Song W; Chen X
ACS Biomater Sci Eng; 2023 Jul; 9(7):4108-4116. PubMed ID: 35653749
[TBL] [Abstract][Full Text] [Related]
3. OX40/OX40 ligand and its role in precision immune oncology.
Thapa B; Kato S; Nishizaki D; Miyashita H; Lee S; Nesline MK; Previs RA; Conroy JM; DePietro P; Pabla S; Kurzrock R
Cancer Metastasis Rev; 2024 Mar; ():. PubMed ID: 38526805
[TBL] [Abstract][Full Text] [Related]
4. OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy.
Shibahara I; Saito R; Zhang R; Chonan M; Shoji T; Kanamori M; Sonoda Y; Kumabe T; Kanehira M; Kikuchi T; So T; Watanabe T; Takahashi H; Iwabuchi E; Tanaka Y; Shibahara Y; Sasano H; Ishii N; Tominaga T
Mol Cancer; 2015 Feb; 14():41. PubMed ID: 25744203
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment.
Chen P; Wang H; Zhao L; Guo H; Zhang L; Zhang W; Sun C; Zhao S; Li W; Zhu J; Yu J; Wu C; He Y
Front Oncol; 2021; 11():713853. PubMed ID: 34900670
[TBL] [Abstract][Full Text] [Related]
6. OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers.
He Y; Zhang X; Jia K; Dziadziuszko R; Zhao S; Deng J; Wang H; Hirsch FR; Zhou C
Transl Lung Cancer Res; 2019 Aug; 8(4):352-366. PubMed ID: 31555511
[TBL] [Abstract][Full Text] [Related]
7. OX40 and OX40L Interaction in Cancer.
Lu X
Curr Med Chem; 2021; 28(28):5659-5673. PubMed ID: 33372866
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma.
Chen X; Ma H; Mo S; Zhang Y; Lu Z; Yu S; Chen J
Front Immunol; 2022; 13():942154. PubMed ID: 35936015
[TBL] [Abstract][Full Text] [Related]
9. OX40 (CD134) and OX40L.
Gough MJ; Weinberg AD
Adv Exp Med Biol; 2009; 647():94-107. PubMed ID: 19760068
[TBL] [Abstract][Full Text] [Related]
10. The significance of OX40 and OX40L to T-cell biology and immune disease.
Croft M; So T; Duan W; Soroosh P
Immunol Rev; 2009 May; 229(1):173-91. PubMed ID: 19426222
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity.
Fu Y; Lin Q; Zhang Z; Zhang L
Acta Pharm Sin B; 2020 Mar; 10(3):414-433. PubMed ID: 32140389
[TBL] [Abstract][Full Text] [Related]
12. Characterization of rat OX40 ligand by monoclonal antibody.
Satake Y; Akiba H; Takeda K; Atsuta M; Yagita H; Okumura K
Biochem Biophys Res Commun; 2000 Apr; 270(3):1041-8. PubMed ID: 10772947
[TBL] [Abstract][Full Text] [Related]
13. OX40L/OX40 axis impairs follicular and natural Treg function in human SLE.
Jacquemin C; Augusto JF; Scherlinger M; Gensous N; Forcade E; Douchet I; Levionnois E; Richez C; Lazaro E; Duffau P; Truchetet ME; Seneschal J; Couzi L; Pellegrin JL; Viallard JF; Schaeverbeke T; Pascual V; Contin-Bordes C; Blanco P
JCI Insight; 2018 Dec; 3(24):. PubMed ID: 30568041
[TBL] [Abstract][Full Text] [Related]
14. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis.
Yoshioka T; Nakajima A; Akiba H; Ishiwata T; Asano G; Yoshino S; Yagita H; Okumura K
Eur J Immunol; 2000 Oct; 30(10):2815-23. PubMed ID: 11069062
[TBL] [Abstract][Full Text] [Related]
15. Multiple levels of activation of murine CD8(+) intraepithelial lymphocytes defined by OX40 (CD134) expression: effects on cell-mediated cytotoxicity, IFN-gamma, and IL-10 regulation.
Wang HC; Klein JR
J Immunol; 2001 Dec; 167(12):6717-23. PubMed ID: 11739485
[TBL] [Abstract][Full Text] [Related]
16. The Immune Checkpoint Modulator OX40 and Its Ligand OX40L in NK-Cell Immunosurveillance and Acute Myeloid Leukemia.
Nuebling T; Schumacher CE; Hofmann M; Hagelstein I; Schmiedel BJ; Maurer S; Federmann B; Rothfelder K; Roerden M; Dörfel D; Schneider P; Jung G; Salih HR
Cancer Immunol Res; 2018 Feb; 6(2):209-221. PubMed ID: 29321210
[TBL] [Abstract][Full Text] [Related]
17. OX40 (CD134) and OX40 ligand interaction plays an adjuvant role during in vivo Th2 responses.
Ishii N; Ndhlovu LC; Murata K; Sato T; Kamanaka M; Sugamura K
Eur J Immunol; 2003 Sep; 33(9):2372-81. PubMed ID: 12938213
[TBL] [Abstract][Full Text] [Related]
18. Constitutive OX40/OX40 ligand interaction induces autoimmune-like diseases.
Murata K; Nose M; Ndhlovu LC; Sato T; Sugamura K; Ishii N
J Immunol; 2002 Oct; 169(8):4628-36. PubMed ID: 12370402
[TBL] [Abstract][Full Text] [Related]
19. Targeting OX40 and OX40L for the treatment of autoimmunity and cancer.
Redmond WL; Weinberg AD
Crit Rev Immunol; 2007; 27(5):415-36. PubMed ID: 18197805
[TBL] [Abstract][Full Text] [Related]
20. OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology.
Ishii N; Takahashi T; Soroosh P; Sugamura K
Adv Immunol; 2010; 105():63-98. PubMed ID: 20510730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
